FDA sets out plan to phase out animal testing requirements for monoclonal antibodies
What was demonstrated
No experiment: this is a regulatory policy event. The US Food and Drug Administration announced a plan to reduce, refine or potentially replace animal testing requirements, starting with monoclonal antibodies, and published a 'Roadmap to Reducing Animal Testing in Preclinical Safety Studies'. It named AI-based computational toxicity models, cell line and organoid testing, and organ-on-a-chip systems as alternatives, and said IND applications were encouraged to include such data immediately.
Why it matters
Regulatory acceptance is the main barrier to adoption of organ-on-chip and other non-animal methods. A stated FDA policy direction creates demand for validated human-relevant models.
Caveats
- It is a plan and roadmap, not a completed rule change; guidance changes are expected in phases after a pilot.
- Validation of non-animal methods for regulatory decisions remains incomplete for many endpoints.
- The press release does not specify which 'other drugs' beyond monoclonal antibodies are covered or when.
Technology profiles
Sources
- government report
FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
U.S. Food and Drug Administration, 10 Apr 2025.
Last reviewed 20 Oct 2026.